Tim Cortese

Despite similar 36-week results, chemoradiation showed a statistically significant difference in QOL scores at 3 and 7 weeks vs radiation therapy alone.

Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.

Liso-cel has been approved by the European Commission for the treatment of adult patients with follicular lymphoma who received 2 or more prior lines of systemic therapy.

Based on positive safety data from the third cohort, a safety review committee approved the opening of a fourth cohort as well as more enrollment into the third cohort.

The OSE2101 cancer vaccine plus FOLFIRI chemotherapy demonstrated positive survival data with minimal toxicities in the phase 2 TEDOPaM trial.

James B. Yu, MD, MHS, FASTRO, didn’t always envision himself as a radiation oncologist, but now works tirelessly to treat patients and advance research for genitourinary cancers.

Despite a relatively small, though increasing, level of focus in oncology, radiation-induced heart damage in breast cancer is a relevant clinical problem that needs more attention.

In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.

Ivonescimab demonstrated a broad prolongation of PFS across various prespecified subgroups in patients with treatment-naïve, PD-L1–positive NSCLC.

Results from the phase 3 REZOR trial show a median PFS of 19.3 months with rezivertinib vs 9.6 months with gefitinib in patients with NSCLC.

The CheckMate 9DW trial found that nivolumab and ipilimumab elicited a median OS of 23.7 months compared with 20.6 months from lenvatinib or sorafenib.

Perioperative and adjuvant S-1 and oxaliplatin demonstrated consistent OS and DFS benefits over adjuvant capecitabine and oxaliplatin.

In the phase 3 COMPETE trial, ITM-11 met its primary end point of PFS and showed a favorable trend with respect to OS in GEP-NETs.

Patients with breast cancer who received endocrine therapy alone had improved physical health outcomes compared with those who received chemotherapy.

The FDA has approved 2 denosumab biosimilars for all prior approvals for the reference drugs in patients with cancers and osteoporosis.

Retrospective analyses found that antihistamines added to atezolizumab yielded a 46% OS rate, a 48% CSS rate, and a 23% PFS rate in patients with metastatic urothelial carcinoma.

A retrospective cohort study found that, of Medicare decedents with advanced cancer, 45% experienced potentially aggressive end-of-life care.

Pirtobrutinib demonstrated PFS benefit compared with standard of care in patients with relapsed or refractory CLL in the BRUIN CLL-321 trial.

Pembrolizumab and bevacizumab yielded an ORR of 58.3% vs 12.5% with pembrolizumab monotherapy in patients with platinum-resistant nasopharyngeal carcinoma.

Despite prior relapses, 200 mg of linvoseltamab elicited complete responses or better in 49.6% of patients with relapsed/refractory multiple myeloma.

After treatment with an aromatase inhibitor plus a CDK4/6 inhibitor, switching to camizestrant plus a CDK4/6 inhibitor showed a PFS benefit over remaining on the aromatase inhibitor.

The survival benefit of dacomitinib was improved in real-world settings for patients with EGFR-mutant NSCLC compared with what the ARCHER 1050 trial shows.

The CAN-2409 combination improved survival post-progression vs standard-of-care therapy alone in the phase 2 PaTK02 trial.

Isatuximab plus bortezomib, lenalidomide, and dexamethasone demonstrated enhanced MRD-negativity rates and a PFS benefit in patients with newly diagnosed multiple myeloma.

A phase 1/1b trial found that the triplet combination elicited an ORR of 45.5% and a median PFS of 14.5 months in previously untreated clear cell RCC.

Patient-reported outcomes from CARTITUDE-4 showed a median time to sustained worsening of symptoms of 23.7 months with cilta-cel and 18.9 months with standard of care.

Data show that rucaparib yielded a median OS of 19.4 months compared with 25.4 months with chemotherapy in relapsed BRCA-mutated ovarian carcinoma.

Tambiciclib plus zanubrutinib doubled the expected ORR of zanubrutinib monotherapy, eliciting an ORR of 67% in patients with relapsed or refractory DLBCL.

Updated, comprehensive OS results with the combination in resectable NSCLC will be shared in a future peer-reviewed setting.

The FDA has accepted an NDA and set a PDUFA date of August 18, 2025, for the decision on dordaviprone in H3 K27M-mutant diffuse glioma.